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Background: Nicotinic receptors are important pharmaceutical targets.
Results: Several drug-receptor hydrogen bonding interactions seen in structural models are not functionally relevant, with
variations seen across different ligands and receptor subtypes.
Conclusion: Caution is necessary when extrapolating from structures of model systems to functional receptors.
Significance: Functional validation of drug-receptor interactions can aid drug discovery efforts.
The agonist-binding site of nicotinic acetylcholine receptors
(nAChRs) spans an interface between two subunits of the pen-
tameric receptor. The principal component of this binding site
is contributed by an  subunit, and it binds the cationic moiety
of the nicotinic pharmacophore. The other part of the pharma-
cophore, a hydrogen bond acceptor, has recently been shown to
bind to the complementary non- subunit via the backboneNH
of a conserved Leu. This interaction was predicted by studies of
ACh-binding proteins and confirmed by functional studies of
the neuronal (CNS) nAChR, 42. The ACh-binding protein
structures further suggested that the hydrogen bond to the
backboneNH ismediated by awatermolecule and that a second
hydrogen bonding interaction occurs between the water mole-
cule and the backboneCOof a conservedAsn, also on the non-
subunit. Here, we provide new insights into the nature of the
interactions between the hydrogen bond acceptor of nicotinic
agonists and the complementary subunit backbone.We studied
both the nAChR of the neuromuscular junction (muscle-type)
and aneuronal subtype, (4)2(4)3. In themuscle-type receptor,
bothACh andnicotine showed a strong interactionwith the Leu
NH, but the potent nicotine analog epibatidine did not. This
interaction wasmuch attenuated in the44 receptor. Surpris-
ingly, we found no evidence for a functionally significant inter-
action with the backbone carbonyl of the relevant Asn in either
receptor with an array of agonists.
Nicotinic acetylcholine receptors (nAChRs)2 are ligand-
gated ion channels that propagate neurotransmission in the
central and peripheral nervous systems (1–4). They are acti-
vated by the neurotransmitter acetylcholine (ACh) and also by
nicotine and related compounds. The nAChRs are members of
a superfamily of ligand-gated ion channels called the Cys-loop
(or pentameric) receptors, which also includes receptors for the
neurotransmitters -aminobutyric acid (GABAA and GABAC),
glycine, and serotonin (5, 6). These receptors are implicated in
an assortment of neurological disorders, including Alzheimer
disease, Parkinson disease, schizophrenia, and depression, and
are also essential for learning,memory, and sensory perception.
nAChRs are pentamers, composed of five subunits arranged
symmetrically around a central ion-conducting pore. There are
16mammalian genes that encode 16 homologous but function-
ally distinct nAChR subunits (1–7, 9, 10, 1–4, , , and
). From various combinations of these subunits, 20 active
nAChR subtypes have been established (7). Nicotinic agonists
bind at subunit interfaces, and a combination of structure-
function studies and structural studies of the acetylcholine-
binding proteins (AChBPs), which share considerable sequence
homology with the ligand-binding domain of the nAChR, has
established a detailed binding model (8–10). The  subunits
contribute the principal component of the agonist-binding site,
which binds to the cationic end of agonists. This binding site is
well characterized, consisting of a cation- interaction with
one of several conserved aromatic residues and typically a
hydrogen bond from the NH of the drug to a backbone car-
bonyl (11–13). The natural agonist ACh,which lacks the crucial
NH, does not participate in the latter interaction.
The complementary component of the agonist-binding site
is formed by non- subunits, and recent work has shown that it
involves a hydrogen bonding interaction with the hydrogen
bond acceptor of agonists (e.g. the CO of ACh or the pyridine
nitrogen of nicotine) (Figs. 1 and 2). Crystal structures of ACh-
BPs with several drugs bound produced a binding model in
which two backbone features, a CO and an NH from amino
acids that are 12 residues apart, coordinate a water molecule,
which in turn hydrogen bonds to the hydrogen bond acceptor
of agonists (Fig. 1) (9, 14, 15). In nAChRs, the particular resi-
dues are Asn and Leu, and they are conserved across the family
(Fig. 3; they are Leu andMet, respectively, in the AChBP struc-
ture of Fig. 1A). Because residue numbering varies among dif-
ferent receptors, wewill refer to themsimply as theAsn andLeu
sites, the former contributing a CO and the latter an NH to the
proposed hydrogen bonding array; specific residue numbers
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are noted under “Experimental Procedures.” Recent studies of
the neuronal42nAChRconfirmed that the LeuNHof the2
subunit does hydrogen bond to the pyridine nitrogen of nico-
tine and to the carbonyl oxygen of ACh (16).
In this work, we expanded these studies of hydrogen bonding
interactions involving the complementary subunit in two ways.
First, we considered two new receptor subtypes: a second neu-
ronal form, (4)2(4)3, henceforth referred to as 44; and the
form found at the neuromuscular junction of the peripheral
nervous system, (1)21 (the fetal form; in the adult variant,
the  subunit replaces the  subunit), which we refer to as the
muscle-type receptor. Note that the pharmacology of the mus-
cle-type receptor is quite distinct from that of neuronal recep-
tors such as 42 and 44, most importantly in the fact that
nicotine is quite potent at these neuronal receptors but not at
the receptors of the neuromuscular junction. This distinction
allows smokers to become addicted to nicotine without adverse
peripheral effects. Second, we evaluated the other component
of the proposed hydrogen bonding model, the water-mediated
hydrogen bond to the Asn carbonyl, in both the 44 andmus-
cle-type receptors. Efforts to probe the Asn backbone carbonyl
in the previously studied 42 receptor were thwarted by tech-
nical issues; the nonsense suppression methodology necessary
for these studies was not selective/efficient enough for our
purposes.
Using unnatural amino acid mutagenesis, we found key dif-
ferences in the hydrogen bonding properties of specific drug-
receptor combinations. Interestingly, we found no evidence for
a functionally significant hydrogen bond to the Asn backbone
carbonyl.
EXPERIMENTAL PROCEDURES
Mutagenesis—Nonsense suppression was performed using
techniques described previously on the embryonicmousemus-
cle-type nAChR ((1)21) in the pAMV vector (12) and the
human 44 receptor in the pGEMhe vector. For nonsense
suppression experiments, a TAG (for mutation at Val-108/
Val-110) or TGA (for mutation at Leu-119/Leu-121,
4Leu-108, and 4Leu-119) stop codon was introduced at the
site of interest using the standard Stratagene QuikChange pro-
tocol and verified through sequencing. The1 subunit contains
a background mutation in the transmembrane M2 helix
(1L9S) that is known to lower whole-cell EC50 values. The 1
subunit contains a hemagglutinin epitope in the M3-M4 cyto-
plasmic loop that does not alter EC50 values in control experi-
ments. cDNA was linearized with the restriction enzyme NotI
for muscle-type receptor subunits and with NheI for 4 and 4
subunits. mRNA was prepared by in vitro transcription using
the mMESSAGE mMACHINE T7 kit (Ambion, Austin, TX).
Stage V-VIXenopus laevis oocytes were injectedwithmRNA
at an1:1:: ratio of 10:1:1:1 or 1:1:5:5 for wild-type/conven-
tional mutagenesis or nonsense suppression experiments,
respectively, with the muscle-type receptor. An 4:4 mRNA
ratio of 1:20 was used for nonsense suppression experiments
with the 44 receptor. Control nonsense suppression experi-
ments confirmed that this ratio ensures a 2:3 subunit stoichi-
ometry. -Hydroxy acids and amino acids were appended to
the dinucleotide dCA and enzymatically ligated to the trun-
cated 74-mer amber suppressor tRNATHG73 or opal suppres-
sor tRNA TQOpS as previously described (12). For wild-type
or conventionalmutagenesis experimentswith themuscle-type
receptor, 1–2 ng of mRNA was injected per oocyte in a single
75-nl injection. For nonsense suppression experimentswith the
muscle-type receptor, each cell was injected with 75 nl of a 1:1
mixture ofmRNA (20–25 ng of totalmRNA) and tRNA (10–25
ng). For nonsense suppression experiments with the 44
receptor, each cell was injected with 50 nl of a 1:1 mixture of
mRNA (50 ng of totalmRNA) and tRNA (25 ng). Amino acids
bearing a 6-nitroveratryloxycarbonyl protecting group were
FIGURE 1.Proposedbindingmodel for nicotine at nAChRs.A, crystal struc-
tureof nicotinebound toAChBP (ProteinDataBank code1UW6).B, schematic
of binding model denoting the key interactions probed here.
FIGURE 2.A, agonists used in this study. B, illustration of amide-to-estermuta-
tion. Introduction of an -hydroxy acid in place of an amino acid eliminates
the hydrogen bond donor (backbone NH) of the i residue and attenuates the
hydrogen bond-accepting ability of the i1 carbonyl. The attenuated hydro-
gen bond is represented by dashed lines.
FIGURE 3. Sequences of the complementary subunits considered here.
The hydrogen bond-donating Leu and hydrogen bond-accepting Asn are
highlighted. The key residues are highly conserved in other orthologs. Resi-
due numbering is for the 2 subunit.
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deprotected prior to injection via irradiation with a 500-watt
mercury/xenon arc lamp, filtered withWG-334 and UG-11 fil-
ters prior to injection. Oocytes were incubated at 18 °C for
16–20 or 24–48 h after injection for the wild-type/conven-
tional mutagenesis or nonsense suppression experiments,
respectively, with themuscle-type receptor.Oocyteswere incu-
bated for 48 h after injection for nonsense suppression experi-
ments with the 44 receptor. Wild-type recovery control
experiments (injection of tRNA appended to the natural amino
acid) were performed to evaluate the fidelity of the nonsense
suppression experiments. In additional control experiments
with the muscle-type receptor, injections of mRNA only and
mRNAwith 76-mer THG73 or TQOpS gaveminimal currents
in electrophysiology experiments (100 nA or less for controls
compared with 2 A for nonsense suppression experi-
ments). For the 44 receptor, injections of mRNA with
76-mer TQOpS gave no detectable currents.
Electrophysiology—Two-electrode voltage clamp electro-
physiology was used to measure the functional effects of each
mutation. Electrophysiology recordings were performed after
injection and incubation as described above using the OpusX-
press 6000A system (Axon Instruments) at a holding potential
of60mV. The running buffer was a Ca2-free ND96 solution
(96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH
7.5). Agonist doses in Ca2-free ND96 were applied for 15 s,
followed by a 116-s washwith the running buffer. Cells express-
ing muscle-type receptors containing the 1G153K mutation
were given longer exposures to agonist (90 s). Acetylcholine
chloride, ()-nicotine tartrate, and ()-cytisine were pur-
chased from Sigma-Aldrich/RBI, ()-epibatidine was pur-
chased fromTocris, and varenicline tartrate was a generous gift
from Pfizer. Dose-response data were obtained for eight or
more agonist concentrations on eight or more cells. Dose-re-
sponse relations were fit to theHill equation to obtain EC50 and
Hill coefficient values, which are reported as means  S.E. of
the fit.
RESULTS
General Strategy—The two hydrogen bonding interactions
being considered here involve the protein backbone, and such
interactions can be probed by incorporating-hydroxy analogs
of amino acids at appropriate locations (Fig. 2B). As a probe of
the LeuNH, the strategy is straightforward: the backboneNH is
replaced with an oxygen. Concerning the backbone CO, -hy-
droxy substitution attenuates the hydrogen bonding ability of
the i1 carbonyl by converting it to an ester carbonyl. It is well
established that the carbonyls of esters aremuch poorer hydro-
gen bond acceptors than those of amides. Interestingly, inmany
studies, both quantitative and qualitative, it has been shown
that the two effects associated with backbone ester incorpora-
tion, removal of the NH hydrogen bond donor and attenuation
of the CO hydrogen bond acceptor, can have similar energetic
consequences (17–21). As such, to perturb the Asn CO, we
actually mutated the i1 residue, which is Leu in the 44
receptor and Val in the muscle-type receptor. Backbone ester
mutations can be efficiently incorporated site-specifically into
nAChRs expressed in Xenopus oocytes by nonsense suppres-
sion methodology (22, 23). Typical experimental traces and
dose-response relations for unnatural amino acid mutagenesis
experiments with these receptors have been reported previ-
ously (12, 13).
These studies use EC50, the effective agonist concentration
needed to reach a half-maximal response, as a readout of the
functional impact of each mutation. It is well recognized that
EC50 is a composite measure, reflecting multiple equilibria that
include both “binding” events (drug entering/exiting the ago-
nist-binding site) and “gating” events (the equilibria between
open and closed states of the channel). It is typical in an EC50
study to note an ambiguity as to whether a given mutation
affects binding or gating. We would argue that, in the present
system, as inmany similar previous studies fromour laboratory,
the ambiguity is of a different kind. Given the subtlety and pre-
cision of the modifications enabled by unnatural amino acid
mutagenesis, combined with our structural knowledge of the
binding site and the location of the mutations made, it is clear
that we are perturbing a hydrogen bonding interaction between
the drug and the receptor, a binding interaction. To see a
change in EC50, it must be true that the hydrogen bonding
interaction is diminished (or enhanced) in one or more of the
multiple equilibria noted above. In the studies presented here,
the ambiguity in the EC50 measurement concerns which equi-
librium is perturbed, not the nature of the perturbation, which
is clearly an attenuated binding interaction.
Detailed kinetic analyses, typically at the single-channel level,
can often determine which equilibrium step(s) is being per-
turbed. However, we consider EC50 to be an appropriatemetric
here for two reasons. First, detailed single-channel studies are
not feasible for the large number of drug-receptor combina-
tions that we have considered. This is especially so, given the
protein expression limitations that are sometimes seen with
unnatural amino acid mutagenesis. Second and more impor-
tantly, our goal is to make pharmacological comparisons
among closely related systems in response to subtle structural
changes. We also wish to compare these results to those of
previous studies on related systems. EC50 is a good measure of
pharmacological activity. Given our experience with these sys-
tems and unnatural amino acid mutagenesis in particular, we
consider EC50 differences of less than a factor of 2 to be not
interpretable.
For studies of the muscle-type receptor, we used the known
L9S mutation in the M2 transmembrane helix of the 1 sub-
unit (where 9 is the ninth amino acid from the cytoplasmic end
of the M2  helix) (24, 25). This mutation was introduced to
generically increase the sensitivity of the protein to agonists,
and it resulted in a systematic40-fold decrease in EC50. Given
that the 9position is60Åaway from the agonist-binding site,
this mutation is generally expected to affect primarily gating
and not agonist binding, although complications can arise (26).
We performed backbone ester mutagenesis of the Leu NH in
the muscle-type receptor in both the absence and presence of
the L9S background mutation, and similar shifts in EC50 were
seen for ACh (see Table 3). This confirms the viability of this
strategy in the present system. The agonist concentrations that
were required to obtain a dose-response relation for epiba-
tidine, nicotine, and choline in the absence of the L9Smutation
were high enough that channel block by the agonist became a
Binding to the Complementary Subunit of Nicotinic Receptors
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problem with some mutants, so all comparisons for this recep-
tor were done using the L9Smutation. An analogousmutation
was also used in the studies of 42 (12). No suchmodification
was necessary for the 44 receptor.
To facilitate discussion, we collected the key data (the -fold
shifts in EC50 values for backbonemutants) into Tables 1 and 2.
Full EC50 values andHill coefficients are given inTables 3 and 4.
Mutagenesis Studies of the Leu NH—To probe for the pre-
sumedhydrogen bond to the Leu backboneNH, the leucinewas
replaced with its -hydroxy acid analog (-hydroxyleucine). In
the muscle-type receptor, ACh and nicotine both showed sub-
stantial increases in EC50 (Table 1), confirming that the back-
bone NH is important for receptor activation by these agonists.
Surprisingly, epibatidine, a nicotine analog that is quite potent
at the muscle-type nAChR (although300-fold less so than at
the 42 subtype), was unresponsive to the backbone ester
mutation. This contrasts with the 5-fold increase in EC50 seen
in the 42 receptor for the analogous mutation with epiba-
tidine as agonist. As expected, choline, which lacks the CO that
serves as the hydrogen bond acceptor, was unresponsive to the
backbonemutation, giving no shift in EC50 upon incorporation
of the -hydroxy acid.
We have shown previously that introduction of a single
mutation in the 1 subunit of the muscle-type receptor,
1G153K, has dramatic effects on the EC50 for nicotine and
that the increased potency of nicotine is, at least in part, a con-
sequence of an enhanced cation- interaction with nicotine in
the mutant muscle-type receptor (12). In the present study, we
found that the 1G153K mutation had little effect on the mag-
nitude of the EC50 -fold shifts seen for ACh or choline in
response to the backbone mutation at Leu (Table 3). A small
increase in the -fold shift in EC50 was seen for nicotine and
epibatidine, suggesting that perhaps the 1G153K mutation
has a modest effect on agonist binding to the Leu residue for
these agonists.
Surprisingly, the analogous mutation of Leu to -hydroxy-
leucine in the 44 receptor showed small to negligible effects
for ACh, nicotine, epibatidine, varenicline, and (as expected)
choline (Table 2). Cytisine showed a large response, establish-
ing that the Leu NH can function as a hydrogen bond donor to
an agonist in the 44 receptor.
Mutagenesis Studies of the Asn CO—The second hydrogen
bond predicted by the AChBP structures is to the backbone CO
of a conserved Asn. To probe for a hydrogen bond to this back-
bone CO, the i1 residue (Val in the muscle-type receptor and
Leu in the 44 receptor) was replaced with its -hydroxy acid
analog (-hydroxyvaline for Val or -hydroxyleucine for Leu).
As discussed above, this converts a backbone amide to a back-
bone ester, thereby attenuating the hydrogen bond-accepting
ability of this moiety.
Early efforts to probe the CO of the relevant Asn residue in
the 42 receptor gave inconsistent results that led us to ques-
tion whether we could reliably control the stoichiometry of the
mutant receptor (27). Because the muscle-type receptor reli-
ably assembles into just one stoichiometry ((1)21), we
anticipated that comparable experiments would experience
fewer complications, and indeed, nonsense suppression studies
at the appropriate Val gave functional mutant receptors. How-
ever, ACh, nicotine, epibatidine, and choline were not signifi-
cantly impacted by the backbone ester mutation (Table 1).
With the experience gained from the muscle-type receptor,
wewere able to probe the keyAsn carbonyl in a neuronal recep-
tor, 44. Again, we found no evidence for a meaningful inter-
action with the carbonyl for the agonists ACh, nicotine, epiba-
tidine, varenicline, cytisine, and choline (Table 2).
DISCUSSION
In recent years, the well studied nicotinic pharmacophore,
composed of a cationic nitrogen and a hydrogen bond acceptor
(28), has been mapped onto specific binding interactions in the
nAChR (Fig. 1). The cationic nitrogen binds to the principal
component of the agonist-binding site in the  subunit, and the
hydrogen bond acceptor binds to the complementary non-
subunit. Guided by structures of AChBP, backbone mutagene-
sis studies established a hydrogen bond between the pharma-
cophore acceptor (the pyridine nitrogen of nicotine and the
carbonyl oxygen of ACh) and a Leu backbone NH in the neu-
ronal 42 nAChR. It is important to note that it is not just the
rise in EC50 resulting from the backbone mutation that estab-
lishes a hydrogen bond. In all cases, choline, which lacks the
hydrogen bond acceptor of the other agonists, is unaffected by
the backbonemutation, proving a direct link between themuta-
tion and the hydrogen bond acceptor of agonists. In our previ-
ous experiments with the 42 subtype, we also studied the
nicotine analog S-N-methyl-2-phenylpyrrolidine (16). In this
structure, the pyridyl ring of nicotine is replaced with a phenyl
ring, providing an alternative way to probe the hydrogen bond-
accepting pyridine nitrogen. This is a more subtle probe than
the ACh/choline comparison, and it provided a compelling link
between the hydrogen bond acceptor of nicotine and the back-
bone NH in the 42 receptor. In the present systems, we were
unable to perform comparable studies with S-N-methyl-2-phe-
nylpyrrolidine because the low potency of this compound at the
receptors considered here required agonist concentrations that
produced competing channel block of the receptor in dose-
response studies.Nevertheless, the studies of the42 receptor
provide support for the idea that mutations of the Leu NH are
perturbing a hydrogen bond to the agonist.
It is worth emphasizing that, although we consider the pres-
ent work as probing hydrogen bonding interactions, we are in
TABLE 1
Shifts in EC50 values for backbonemutants of the muscle-type receptor
Values are EC50(mutant)/EC50(wild type). Lah, -hydroxyleucine; Vah, -hydroxyvaline.
ACh Nicotine Epibatidine Choline
Probing Leu NHLeu-Lah mutation 29 10 1.3 1.3
Probing Asn COVal-Vah mutation 1.4 2.2 1.0 1.3
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fact probing the functional significance of particular hydrogen
bonds. Thus, it is possible that a structural study could show the
presence of a hydrogen bond, but if deleting/attenuating that
hydrogen bond has no functional consequence, it would show
up as no hydrogen bond in our assay. We first discuss our find-
ings concerning the contribution of the Leu backbone NH.
ACh and nicotine both show a strong hydrogen bonding
interaction with the Leu backbone NH in the muscle-type
receptor. Nicotine shows very poor potency at the wild-type
muscle receptor, and so we were surprised to find that nicotine
is very sensitive to the Leu backbone ester mutation, more sen-
sitive than it is to the corresponding mutation in the 42
receptor, in which nicotine is a very potent agonist. This muta-
tion also impacts ACh potency much more in the muscle-type
receptor than in the42 receptor.We have performed similar
backbone mutations at locations throughout the nAChR to
probe for various hydrogen bonds, andwe typically saw inform-
ative but modest increases in EC50 of5–20-fold. The 29-fold
increase in EC50 seen for ACh in the muscle-type receptor is
among the largest responses we have seen for a backbone ester
mutation. It is alsomuch larger than the 7-fold increase seen for
the equivalent mutation in the 42 receptor (16). These
results may suggest that the hydrogen bond to the Leu NH is
stronger in themuscle-type receptor, and it is possible thatACh
and nicotine sit more closely to this residue in the muscle-type
receptor than they do in the42 subtype. As expected, choline
as an agonist is unresponsive to this mutation.
Surprisingly, epibatidine, a potent agonist at themuscle-type
receptor, is unresponsive to the Leu backboneNHmutation. In
crystal structures ofAChBPbindingnicotine or epibatidine, the
relative positioning of all relevant atoms, the pyridine nitrogen
and the backbone NH and CO, is essentially identical. As such,
it has been assumed that these two closely related molecules
bind in the same way, even though the bridging water is not
observable in the epibatidine structure, presumably because
it is not ordered enough for the relatively low resolution
structure.
One possible explanation for the lack of a functionally signif-
icant hydrogen bonding interaction with the pyridine nitrogen
of epibatidine in themuscle-type receptor is that the nitrogen is
a relatively poor hydrogen bond acceptor. When considering
closely related systems, pKa is an excellent predictor of hydro-
TABLE 2
Shifts in EC50 values for backbonemutants of the 44 receptor
Values are EC50(mutant)/EC50(wild type). Lah, -hydroxyleucine.
ACh Nicotine Epibatidine Varenicline Cytisine Choline
Probing Leu NHLeu-Lah mutation 2.9 2.8 1.9 0.38 14 1.4
Probing Asn COLeu-Lah mutation 0.86 0.89 1.3 2.0 0.61 0.92
TABLE 3
EC50 and Hill coefficient values (mean S.E.) for mutations in the muscle-type receptor
Mutations identified as Leu and Val represent recovery of the wild-type receptor by nonsense suppression. Mutations denoted with an asterisk have the L9S mutation.
Lah, -hydroxyleucine; Vah, -hydroxyvaline.
Mutation Drug EC50 Hill
M
Wild type ACh 16.0 0.3 1.3 0.1
L119Leu/L121Leu ACh 16.0 0.5 1.5 0.1
L119Lah/L121Lah ACh 230 6 1.5 0.1
Wild type* ACh 0.61 0.04 1.4 0.1
L119Leu/L121Leu* ACh 0.31 0.02 1.5 0.1
L119Lah/L121Lah* ACh 9.1 0.7 1.6 0.2
Wild type* Choline 840 20 1.6 0.1
L119Leu/L121Leu* Choline 780 30 1.7 0.1
L119Lah/L121Lah* Choline 1000.00 0.05 1.8 0.1
Wild type* ()-Epibatidine 0.32 0.02 1.5 0.1
L119Leu/L121Leu* ()-Epibatidine 0.40 0.02 1.5 0.1
L119Lah/L121Lah* ()-Epibatidine 0.52 0.03 1.6 0.1
Wild type* S-Nicotine 22.0 0.8 1.6 0.1
L119Leu/L121Leu* S-Nicotine 23 0.7 1.7 0.1
L119Lah/L121Lah* S-Nicotine 230 30 2.2 0.5
V108Val/V110Val* ACh 0.29 0.01 1.3 0.1
V108Vah/V110Vah* ACh 0.41 0.05 1.2 0.2
V108Val/V110Val* Choline 620 20 1.4 0.1
V108Vah/V110Vah* Choline 790 60 1.4 0.1
V108Val/V110Val* ()-Epibatidine 0.230 0.006 1.4 0.1
V108Vah/V110Vah* ()-Epibatidine 0.240 0.006 1.5 0.1
V108Val/V110Val* S-Nicotine 15 1 1.2 0.1
V108Vah/V110Vah* S-Nicotine 33 2 1.6 0.1
1G153K* ACh 0.0072 0.0007 1.3 0.1
1G153K/L119Leu/L121Leu* ACh 0.0076 0.0007 1.8 0.3
1G153K/L119Lah/L121Lah* ACh 0.18 0.02 1.3 0.1
1G153K* Choline 30 2 1.0 0.1
1G153K/L119Leu/L121Leu* Choline 27 2 1.1 0.1
1G153K/L119Lah/L121Lah* Choline 68 3 1.3 0.1
1G153K* ()-Epibatidine 0.0043 0.0005 0.77 0.5
1G153K/L119Leu/L121Leu* ()-Epibatidine 0.0023 0.0004 0.74 0.1
1G153K/L119Lah/L121Lah* ()-Epibatidine 0.0096 0.0004 1.1 0.1
1G153K* S-Nicotine 0.32 0.03 1.4 0.2
1G153K/L119Leu/L121Leu* S-Nicotine 0.36 0.04 0.95 0.1
1G153K/L119Lah/L121Lah* S-Nicotine 6.5 0.5 1.3 0.1
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gen bonding ability. Pyridine, a good model for nicotine, has a
pKa of 5.2, but 2-chloropyridine, a model for epibatidine, has a
much lower pKa of 0.5 (29). Thus, epibatidine is expected to be
a poorer base than nicotine by5 orders ofmagnitude, and it is
safe to conclude that epibatidine would also be a much poorer
hydrogen bond acceptor. Recently, we showed that varenicline,
the smoking cessation compoundmarketed as Chantix®, is sim-
ilarly unresponsive to the analogous backbone NHmutation in
the 42 receptor (30). The quinoxaline nitrogens of vareni-
cline have a pKa of 0.8, quite similar to that for epibatidine.
Thus, in these two very potent nicotinic agonists, epibatidine
and varenicline, the strength of the hydrogen bond acceptor is
expected to be greatly attenuated, and our functional assay for
this hydrogen bond appears to reflect this property.
Earlier studies showed that the identity of the residue at posi-
tion 153 of the1 subunit strongly impacts receptor function in
the muscle-type receptor. An 1G153K mutation in the mus-
cle-type receptor greatly increases nicotine potency, and it does
so by facilitating a strong cation- interaction with TrpB that is
absent in the wild-type receptor. We have now found that the
1G153K mutation does not have a substantial impact on the
Leu backbone NH interaction. This is perhaps not surprising,
given that the 1Gly-153 residue is located in the principal
component of the agonist-binding site, whereas the Leu residue
lies across the subunit interface in the complementary compo-
nent of the binding site.
When we probed the Leu backbone NH interaction in the
44 receptor, we found a much smaller impact of the back-
bone mutation. ACh and nicotine showed meaningful but
much smaller effects than is usual; in 42 receptors, the effect
ranged from 5.6- to 8.5-fold for the same agonists. Again, epi-
batidine showed no meaningful effect, and varenicline actually
showed a small gain of function. Cytisine, another compound
that is marketed for smoking cessation under the brand name
Tabex, showed a large effect. The hydrogen bond acceptor in
cytisine is not a pyridine-type nitrogen but is rather the oxygen
of an amide carbonyl. Amides are much stronger hydrogen
bond acceptors, and indeed, we saw very large effects for cyti-
sine at the 42 receptor. For the two stoichiometries of 42,
2:3 and 3:2, the backbone NHmutation led to perturbations of
62- and 14-fold, respectively, with cytisine as the agonist.
The second component of the interaction with the hydrogen
bond acceptor of nicotinic agonists predicted by AChBP struc-
tures is the water-mediated hydrogen bond to the Asn back-
bone CO. Using the backbone ester strategy to perturb this
proposed interaction, we measured nine different drug-recep-
tor interactions involving two different receptors, and in no
case, did we see a meaningful interaction (not including cho-
line, for which no effect is expected). The strongest effects were
for varenicline at the 44 receptor, with a ratio of 2.0, and for
nicotine at the muscle-type receptor, with a ratio of 2.2, barely
what we consider to be meaningful. All other effects were less
than a factor of 2.
Note that the strategy employed here to probe a hydrogen
bond to a backbone carbonyl can produce large effects. In
nicotinic receptors, when we used the strategy to probe the
interaction of the NH of the drug with the backbone car-
bonyl of the key Trp residue of the binding site (Fig. 1), EC50
shifts ranged from 9- to 27-fold for potent drug-receptor
combinations.
We thus conclude that the water-mediated interaction
between the hydrogen bond acceptor of agonists and the Asn
backbone CO seen in AChBP structures is not functionally sig-
nificant in nAChRs in general. We note that there is a funda-
mental distinction between the two hydrogen bonds seen in
AChBP. If the water molecule were not present, the Leu back-
bone NH could donate a hydrogen bond directly to the hydro-
gen bond acceptor of agonists. In contrast, the Asn backbone
CO is itself a hydrogen bond acceptor, and so it can interact
with the hydrogen bond acceptor of agonists only through an
intermediary water. Our results thus open up the possibility
that the water molecule that is seen in essentially all AChBP
structures is not present in actual receptors.Whether the water
molecule is or is not present, we found that perturbing its puta-
tive hydrogen bonding partner has little consequence on recep-
tor function.
In the pharmacology of nicotinic receptors, it has often been
suggested that the complementary non- subunit plays a key
role in establishing subtype selectivity for various drugs. We
have now probed the complementary binding site for four nic-
otinic subtypes (muscle-type, 44, and both stoichiometries
of 42) and observed interesting variations for particular
drug-receptor combinations. We believe that this information
will be of value to efforts to develop more selective drugs that
target nicotinic receptors.
Wehave shown thatACh and nicotine both engage in a func-
tionally important hydrogen bond to the complementary sub-
unit Leu backbone NH in the muscle-type nAChR, but the nic-
otine analog epibatidine does not. In the 44 receptor,
interactions with the Leu backbone NH are surprisingly weak.
We also found no evidence for a functionally important water-
mediated hydrogen bond to the Asn backbone CO. Our results
TABLE 4
EC50 and Hill coefficient values (mean  S.E.) for mutations made to
the the 44 receptor
Mutations identified as Leu represent recovery of the wild-type receptor by non-
sense suppression. Lah, -hydroxyleucine.
Mutation Drug EC50 Hill
M
4L108Leu ACh 15.2 0.9 1.43 0.09
4L108Lah ACh 13 2 1.2 0.2
4L108Leu S-Nicotine 1.9 0.2 1.3 0.1
4L108Lah S-Nicotine 1.7 0.2 1.4 0.1
4L108Leu ()-Epibatidine 0.0050 0.0002 1.70 0.08
4L108Lah ()-Epibatidine 0.0065 0.0002 1.71 0.08
4L108Leu Varenicline 0.120 0.004 1.38 0.05
4L108Lah Varenicline 0.24 0.01 1.19 0.05
4L108Leu ()-Cytisine 0.227 0.005 1.42 0.04
4L108Lah ()-Cytisine 0.139 0.007 1.40 0.08
4L108Leu Choline 1200 70 1.62 0.09
4L108Lah Choline 1100 100 1.4 0.1
4L119Leu ACh 15.0 0.7 1.42 0.08
4L119Lah ACh 43 4 1.5 0.2
4L119Leu S-Nicotine 2.1 0.2 1.3 0.1
4L119Lah S-Nicotine 5.8 0.4 1.4 0.1
4L119Leu ()-Epibatidine 0.0055 0.0001 1.80 0.05
4L119Lah ()-Epibatidine 0.01018 0.00009 1.63 0.02
4L119Leu Varenicline 0.133 0.002 1.37 0.02
4L119Lah Varenicline 0.050 0.003 1.5 0.1
4L119Leu ()-Cytisine 0.229 0.004 1.37 0.02
4L119Lah ()-Cytisine 3.1 0.1 1.37 0.05
4L119Leu Choline 1400 300 1.4 0.2
4L119Lah Choline 2000 700 1.1 0.2
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highlight the necessity of functional studies on intact receptors
to probe interactions suggested by structural studies of model
systems.
Acknowledgment—We thank Pfizer for the generous gift of
varenicline.
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